in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a reshuffle at PhRMA and manoeuvring of directors at OSI Pharmaceuticals and Biogen Idec.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Genzyme strengthening its manufacturing team and Carl Icahn’s representative joining Adventrex’s board.
Big pharma's lust for biotech's pipelines appears to be continuing
unabated with a record $27bn-worth of acquisitions and licensing
deals being made last year.
The man often credited with causing Biogen Idec to be put up for
sale, billionaire corporate raider Carl Icahn, has invested in
Genzyme and promptly started industry tongues wagging about a
takeover.
Novo Nordisk, Rheosciences, ImClone, Omrix Biopharmaceuticals,
Biogen Idec and Human Genome Sciences, have all had people on the
move in the biotech world.
Investment mogul Carl Icahn could get ready to buy further shares
of biotech company Biogen Idec after getting the green light from
the competition regulators.
